Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK112 combination therapy in advanced hepatocellular carcinoma
CTR20243030Phase 2Active
- Sponsor
- CTTQ-Akeso
- Start
- Sep 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in hepatocellular carcinoma (HCC), sponsored by CTTQ-Akeso. Started Sep 2024; status: active.
02
Drugs
ivonescimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243030.